This what happened from new blurbTG Therapeutics acquired the global rights to Azer-cel (Azercabtagene Zapreleucel) from Precision BioSciences in January 2024. The deal gave TG Therapeutics exclusive rights to develop Azer-cel for autoimmune diseases and other non-cancer indications, with an upfront payment of $17.5 million and additional milestone payments of up to $288 million(
Following the announcement, TG Therapeutics' share price saw an increase, reflecting investor optimism about the expansion of their portfolio into the promising field of CAR T-cell therapies for autoimmune diseases. This move was seen as a strategic enhancement of TG Therapeutics' existing focus on B-cell disorders, especially with their successful development of Briumvi for multiple sclerosis. However, the exact share price impact varied over time as the market responded to clinical progress and broader industry conditions
Now if ASX and PH are the problem here in Australia what can IMU do ....
This what happened from new blurbTG Therapeutics acquired the...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.002(4.00%) |
Mkt cap ! $356.9M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.1¢ | 4.8¢ | $1.062M | 21.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 5138497 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.9¢ | 6291273 | 3 |
View Market Depth
| Last trade - 16.10pm 17/09/2024 (20 minute delay) ? |
| IMU (ASX) Chart |